<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571086</url>
  </required_header>
  <id_info>
    <org_study_id>FAPI PET REG</org_study_id>
    <nct_id>NCT04571086</nct_id>
  </id_info>
  <brief_title>FAPI-PET for Tumor Detection</brief_title>
  <official_title>68-Ga-FAPI-PET for Tumor Detection: A Prospective Observational Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational trial investigating correlation with histopathology,&#xD;
      positive predictive value, detection rate, reproducibility and impact on clinical management&#xD;
      of 68-Ga-FAPI PET/CT or PET/MRI in patients receiving this imaging modality for tumor staging&#xD;
      or restaging as part of clinical care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      68-Ga-fibroblast-activation-protein-inhibitors (68-Ga-FAPI) are novel Positron emission&#xD;
      tomography (PET) tracers that were recently introduced for the imaging of patients with&#xD;
      various cancer diseases. The fibroblast-activation-protein (FAP) is highly expressed in&#xD;
      carcinoma-associated fibroblasts (CAFs) in the stroma of various tumor entities. The aim of&#xD;
      this registry study is to collect data on FAPI expression, positive predictive value,&#xD;
      detection rate, reproducibility and impact on clinical management of 68-Ga-FAPI PET/CT or&#xD;
      PET/MRI on patients receiving this imaging modality at initial diagnosis or restaging as part&#xD;
      of clinical care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Correlation between 68Ga-FAPI PET uptake intensity and histopathologic FAP expression. Validation via immunohistochemical FAP staining/molecular analyses of pathological specimen.</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection rate on a per-patient-basis of FAPI-PET for detection of tumor location, confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection rate on a per-region-basis of FAPI-PET for detection of tumor location, confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV) on a per-patient-basis of FAPI-PET for detection of tumor location, confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV) on a per-region-basis of FAPI-PET for detection of tumor location, confirmed by histopathology/biopsy, clinical and conventional imaging follow-up.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of FAPI PET on a per-patient and per-region-basis for detection of tumor location confirmed by histopathology/biopsy (separate for regional, extra-regional and distant locations)</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on patient management assessed by pre- and post-imaging questionnaires</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection rates on a per-patient basis of FAPI-PET stratified by tumor maker serum level and velocity</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of up- or downstaging following FAPI-PET imaging.</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Malignant Neoplasm</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples, tissue samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for FAPI-PET for tumor staging or restaging&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. FAPI-PET scheduled for staging or restaging as part of clinical routine for proven or&#xD;
             suspected malignancy&#xD;
&#xD;
          2. Age â‰¥ 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient cannot give consent for the study&#xD;
&#xD;
          2. Patient can not lie flat or tolerate FAPI PET imaging&#xD;
&#xD;
          3. Unwillingness or inability to comply with study and follow-up procedures&#xD;
&#xD;
          4. Condition of patient which is critical to participate in this study in the discretion&#xD;
             of the investigators&#xD;
&#xD;
          5. Pregnant, lactating, or breast feeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Fendler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolfgang Fendler, MD</last_name>
    <phone>+49 201 723 1862</phone>
    <email>wolfgang.fendler@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lukas Kessler, MD</last_name>
    <phone>+49 201 723 1862</phone>
    <email>lukas.kessler@uk-essen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nuclear medicine, University hospital Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Fendler, MD</last_name>
      <phone>+49 201 723 1862</phone>
      <email>wolfgang.fendler@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Lukas Kessler, MD</last_name>
      <phone>+49 201 723 1862</phone>
      <email>lukas.Kessler@uk-essen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Wolfgang Fendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Siveke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nader Hirmas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Kessler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Wolfgang Fendler</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>FAPI</keyword>
  <keyword>cancer</keyword>
  <keyword>Positron-Emission-Tomography</keyword>
  <keyword>FAP</keyword>
  <keyword>fibroblast</keyword>
  <keyword>imaging</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

